← Insider buys
CRVS

Corvus Pharmaceuticals, Inc. · Healthcare

Director and 10% owner Peter A. Thompson sold $6.8M of Corvus Pharmaceuticals, Inc.

Sold$6,757,732
$6.09Price
1,109,644Shares
−14%Stake

What CRVS did after the filing

Filed Sep 22Copier in Sep 23
The stock from Thu, Sep 23 open, $7.21
−28.4%
S&P 500, same days
+6.2%

Measured over 30 trading days, to the Nov 4 close.

Traded Mon, Sep 20. Filed Wed, Sep 22, 5:24 PM ET, after the close. Returns use the Sep 23 open and the Nov 4 close. Not investment advice.